Department of Ophthalmology (HJ, JW), Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; Department of Neurology (HJ, BEL, BSB, CJC, TR), University of Miami Miller School of Medicine, Miami, Florida; and Department of Kinesiology and Sports Sciences (JFS), University of Miami, Miami, Florida.
J Neuroophthalmol. 2021 Jun 1;41(2):251-260. doi: 10.1097/WNO.0000000000001140.
Alzheimer disease (AD) is a heterogeneous and multifactorial disorder with an insidious onset and slowly progressive disease course. To date, there are no effective treatments, but biomarkers for early diagnosis and monitoring of disease progression offer a promising first step in developing and testing potential interventions. Cerebral vascular imaging biomarkers to assess the contributions of vascular dysfunction to AD are strongly recommended to be integrated into the current amyloid-β (Aβ) [A], tau [T], and neurodegeneration [(N)]-the "AT(N)" biomarker system for clinical research. However, the methodology is expensive and often requires invasive procedures to document cerebral vascular dysfunction. The retina has been used as a surrogate to study cerebral vascular changes. There is growing interest in the identification of retinal microvascular changes as a safe, easily accessible, low cost, and time-efficient approach to enhancing our understanding of the vascular pathogenesis associated with AD.
A systemic review of the literature was performed regarding retinal vascular changes in AD and its prodromal stages, focusing on functional and structural changes of large retinal vessels (vessels visible on fundus photographs) and microvasculature (precapillary arterioles, capillary, and postcapillary venules) that are invisible on fundus photographs.
Static and dynamic retinal microvascular alterations such as retinal arterial wall motion, blood flow rate, and microvascular network density were reported in AD, mild cognitive impairment, and even in the preclinical stages of the disease. The data are somewhat controversial and inconsistent among the articles reviewed and were obtained based on cross-sectional studies that used different patient cohorts, equipment, techniques, and analysis methods.
Retinal microvascular alterations exist across the AD spectrum. Further large scale, within-subject longitudinal studies using standardized imaging and analytical methods may advance our knowledge concerning vascular contributions to the pathogenesis of AD.
阿尔茨海默病(AD)是一种异质性和多因素疾病,其发病隐匿,疾病进程缓慢。迄今为止,尚无有效的治疗方法,但生物标志物可用于早期诊断和监测疾病进展,为开发和测试潜在干预措施提供了有希望的第一步。强烈建议将评估血管功能障碍对 AD 贡献的脑血管成像生物标志物纳入当前的淀粉样蛋白-β(Aβ)[A]、tau [T]和神经退行性变[(N)]-用于临床研究的“AT(N)”生物标志物系统。然而,该方法费用昂贵,通常需要进行有创操作才能记录脑血管功能障碍。视网膜已被用作研究脑血管变化的替代物。人们越来越关注识别视网膜微血管变化,因为它是一种安全、易于获取、低成本且高效的方法,可以增强我们对与 AD 相关的血管发病机制的理解。
对 AD 及其前驱期视网膜血管变化进行了系统的文献回顾,重点关注大视网膜血管(眼底照片上可见的血管)和微血管(毛细血管前小动脉、毛细血管和小静脉后段)的功能和结构变化。眼底照片上看不见这些小血管。
在 AD、轻度认知障碍,甚至在疾病的临床前阶段,报告了静态和动态视网膜微血管改变,如视网膜动脉壁运动、血流速度和微血管网络密度。这些数据在综述文章中存在一定的争议和不一致性,并且是基于使用不同患者队列、设备、技术和分析方法的横断面研究获得的。
视网膜微血管改变存在于 AD 谱中。使用标准化成像和分析方法进行更大规模的、个体内的纵向研究可能会增进我们对血管对 AD 发病机制贡献的认识。